EGFR stands for “epidermal growth factor receptor,” which can be targeted by certain cancer therapies. A common side effect of EGFR cancer treatment is an acne-like skin rash that can occur mostly on the face, chest, back, arms, and scalp.

The rash may have the following characteristics:

- It may look like acne, but it is not.
- It may appear red, swollen, crusty, and very dry.
- It may feel itchy, tender, painful, warm, or burning.
- It may cause the skin to change color after the rash has gone away.

It usually starts and is worse within the first few weeks of treatment. It will go away after the treatment is stopped, but not right away.

To lessen the severity of the rash, do the following:

- Avoid direct sunlight on the skin by applying PABA-free SPF 30 sunblock and lip balm, and wear protective hats and clothing in the sunlight.
- Do not use tanning beds.
- Avoid products with perfumes, alcohol, benzoyl peroxide, or salicylic acid (anti-acne products) because they can increase skin dryness and cause further irritation.
- Cleanse your skin regularly with a mild soap, such as Basis® or Cetaphil®, to keep the area from becoming infected.
- Limit showers with hot water because it can dry the skin. Instead, take short showers with warm water.
- After bathing, pat your skin dry, and while it is still a little damp, apply a non-fragrance body cream.

To treat the rash, your doctor may prescribe the following:

- A steroid cream to apply temporarily
- An antibiotic gel to apply to the affected area
- An antibiotic to take by mouth to help treat infection caused by the rash
Call your care team if you experience any of the following symptoms:

- The rash becomes itchy, tender, or painful or looks infected (red, warm to touch).
- The rash is affecting your ability to carry out your normal daily activities.
- The appearance of the rash is bothering you.
- The rash continues to spread despite current treatment.

**Additional instructions**

---

**Important notice:** The Association of Community Cancer Centers (ACCC), Hematology/Oncology Pharmacy Association (HOPA), National Community Oncology Dispensing Association, Inc. (NCODA), and Oncology Nursing Society (ONS) have collaborated in gathering information for and developing this patient education guide. This guide represents a brief summary of the medication derived from information provided by the drug manufacturer and other resources. This guide does not cover all existing information related to the possible uses, directions, doses, precautions, warnings, interactions, adverse effects, or risks associated with this medication and should not substitute for the advice of a qualified healthcare professional. Provision of this guide is for informational purposes only and does not constitute or imply endorsement, recommendation, or favoring of this medication by ACCC, HOPA, NCODA, or ONS, who assume no liability for and cannot ensure the accuracy of the information presented. The collaborators are not making any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional.

**Permission:** Oral Chemotherapy Education (OCE) sheets are provided as a free educational resource for patients with cancer in need of concise, easy-to-understand information about oral cancer drugs. Healthcare providers are permitted to copy and distribute the sheets to patients as well as direct patients to the OCE website for information. However, commercial reproduction or reuse, as well as rebranding or reposting of any type, are strictly prohibited without permission of the copyright holder. Please email permission requests and licensing inquiries to Contact@NCODA.org.

Copyright © 2020. All rights reserved.